GlassScriptPhysician profile
Lori K Morrill
NPI 1073675153
$2,539.63
in general payments reported to CMS, 2019-2025
24 companies · $716 in 2025
The $716 reported for 2025 was more than what 78% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $322 · 2022: $590 · 2023: $711 · 2024: $201 · 2025: $716.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,449 · Education: $179.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,448.52 |
| Education | $179.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $608.03 | 2021-2025 | Xtandi |
| Janssen Biotech, INC. | $321.19 | 2022-2024 | Erleada |
| Sumitomo Pharma America, INC. | $319.97 | 2023-2025 | Gemtesa |
| Teleflex LLC | $217.63 | 2022-2025 | Urolift, Barrigel |
| Urovant Sciences INC | $205.76 | 2021-2022 | |
| Endo Pharmaceuticals INC. | $113.72 | 2022-2023 | Xiaflex, Aveed |
| Biohaven Pharmaceutical Holding Company LTD. | $110.20 | 2022 | |
| Abbvie INC. | $93.47 | 2023-2025 | |
| Boston Scientific Corporation | $73.60 | 2025 | General - Female Sui, Axonics |
| Amneal Pharmaceuticals LLC | $68.43 | 2022-2023 | Rytary |
| Sunovion Pharmaceuticals INC. | $42.12 | 2021-2022 | |
| Lilly USA, LLC | $41.43 | 2023 | Emgality, Reyvow, Amyvid |
| Myovant Sciences INC. | $39.96 | 2022 | |
| Biogen, INC. | $39.57 | 2023 | Vumerity, Tysabri |
| Ferring Pharmaceuticals INC. | $39.27 | 2025 | Adstiladrin |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myriad Genetic Laboratories, INC. | $35.45 | 2025 | Prolaris |
| Kowa Pharmaceuticals America, INC. | $30.49 | 2022-2023 | Seglentis |
| Endo USA, INC. | $27.42 | 2025 | Aveed, Xiaflex |
| Merck Sharp & Dohme LLC | $22.06 | 2024 | Welireg, Keytruda |
| Tolmar Pharmaceuticals, INC. | $21.36 | 2021 | |
| Banner Life Sciences, LLC | $20.12 | 2022 | |
| Neurelis, INC. | $17.27 | 2022 | |
| Mallinckrodt Hospital Products INC. | $16.25 | 2022 | |
| International Rehabilitative Sciences, INC | $14.86 | 2025 | Rs-4i Plus With Intersperse |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lori Morrill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.